Payment overview · 2025
General Payments
$244.11
12 reported records · 7 companies
Healthcare provider profile · identity verified
Thomas D Harper, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GADSDEN, AL · NPI 1912091992
Verified facts
What the public records show
CMS Open Payments records show Thomas D Harper, M.D. received $244.11 in general payments during 2025 across 12 reported records.
Astellas Pharma US Inc accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $83.32 | 34.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.40 | 18.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.57 | 16.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.20 | 9.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.90 | 8.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.14 | 8.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.11 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $29.23 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Izervay Normalized: izervay |
Drug | Astellas Pharma US Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 692 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 676 | 181 |
| Pravastatin Sodium | Pravastatin Sodium | 598 | 162 |
| Lisinopril | Lisinopril | 493 | 132 |
| Losartan Potassium | Losartan Potassium | 464 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 432 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 115 |
| Alprazolam | Alprazolam | 378 | 69 |
| Tramadol Hcl | Tramadol Hcl | 374 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 364 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 343 | 104 |
| Omeprazole | Omeprazole | 341 | 91 |
| Clonazepam | Clonazepam | 335 | 58 |
| Meloxicam | Meloxicam | 307 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 296 | 87 |
| Gabapentin | Gabapentin | 283 | 68 |
| Metformin Hcl | Metformin Hcl | 271 | 68 |
| Potassium Chloride | Potassium Chloride | 266 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 70 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 201 | 49 |
| Alendronate Sodium | Alendronate Sodium | 193 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 187 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 53 |
| Montelukast Sodium | Montelukast Sodium | 180 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 36 |
| Famotidine | Famotidine | 171 | 51 |
| Atenolol | Atenolol | 169 | 45 |
| Lorazepam | Lorazepam | 150 | 31 |
| Glimepiride | Glimepiride | 145 | 36 |
| Trazodone Hcl | Trazodone Hcl | 142 | 33 |
| Januvia | Sitagliptin Phosphate | 141 | 29 |
| Carvedilol | Carvedilol | 140 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 40 |
| Furosemide | Furosemide | 131 | 42 |
| Simvastatin | Simvastatin | 122 | 35 |
| Eliquis | Apixaban | 120 | 30 |
| Donepezil Hcl | Donepezil Hcl | 111 | 25 |
| Glipizide Er | Glipizide | 109 | 28 |
| Allopurinol | Allopurinol | 108 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 26 |
| Fenofibrate | Fenofibrate | 95 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 19 |
| Clonidine Hcl | Clonidine Hcl | 91 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 25 |
| Pregabalin | Pregabalin | 87 | 18 |
| Azithromycin | Azithromycin | 85 | 77 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 26 |
| Cefdinir | Cefdinir | 84 | 80 |
| Sertraline Hcl | Sertraline Hcl | 84 | 24 |
| Memantine Hcl | Memantine Hcl | 83 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 19 |
| Celecoxib | Celecoxib | 75 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 13 |
| Xarelto | Rivaroxaban | 59 | 13 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Irbesartan | Irbesartan | 58 | 16 |
| Nateglinide | Nateglinide | 58 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 13 |
| Ozempic | Semaglutide | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 11 |
| Temazepam | Temazepam | 55 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 25 |
| Meclizine Hcl | Meclizine Hcl | 54 | 30 |
| Lansoprazole | Lansoprazole | 52 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 13 |
| Torsemide | Torsemide | 50 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 21 |
| Enalapril Maleate | Enalapril Maleate | 48 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Terazosin Hcl | Terazosin Hcl | 47 | 14 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 33 |
| Methylprednisolone | Methylprednisolone | 43 | 41 |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Methocarbamol | Methocarbamol | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 13 |
| Glipizide | Glipizide | 40 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 13 |
| Digoxin | Digoxin | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 25 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Klor-Con M10 | Potassium Chloride | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.11 · 12 records | Astellas Pharma US Inc | Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE, Izervay, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error